Page last updated: 2024-08-24

mevastatin and mk 2206

mevastatin has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bjune, K; Leren, TP; Naderi, S; Sundvold, H	1

Other Studies

1 other study(ies) available for mevastatin and mk 2206

Article	Year
MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potential hypocholesterolemic agent. Atherosclerosis, 2018, Volume: 276 Topics: Anticholesteremic Agents; Biological Transport; Cholesterol, LDL; HeLa Cells; Hep G2 Cells; Hepatocytes; Heterocyclic Compounds, 3-Ring; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-akt; Receptors, LDL; Signal Transduction; Sterol Regulatory Element Binding Protein 2	2018

Article

Year

MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potential hypocholesterolemic agent.

Atherosclerosis, 2018, Volume: 276

Topics: Anticholesteremic Agents; Biological Transport; Cholesterol, LDL; HeLa Cells; Hep G2 Cells; Hepatocytes; Heterocyclic Compounds, 3-Ring; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-akt; Receptors, LDL; Signal Transduction; Sterol Regulatory Element Binding Protein 2

2018